MSF Microsoft MSFT · Nasdaq · Technology
SEC EDGAR ↗ SEC EDGAR Filings checked 23 Oct 2026, 16:23 UTC Financials checked 23 Oct 2026, 16:23 UTC
Some records were last checked more than 24 hours ago. These are the last verified records; check the official source for the latest filings.
Annual reporting period: 2025-07-01 — 2026-06-30 · USD
Annual revenue $331.84B Year over year +17.8%
Annual net income $133.75B Consolidated net income
Annual operating income $155.24B Consolidated basis
Operating margin 46.8% Operating income / revenue
Revenue over time ANNUAL
2017-06-30 · 96,571,000,000 USD
2017 $96.57B
2018-06-30 · 110,360,000,000 USD
2018 $110.36B
2019-06-30 · 125,843,000,000 USD
2019 $125.84B
2020-06-30 · 143,015,000,000 USD
2020 $143.02B
2021-06-30 · 168,088,000,000 USD
2021 $168.09B
2022-06-30 · 198,270,000,000 USD
2022 $198.27B
2023-06-30 · 211,915,000,000 USD
2023 $211.92B
2024-06-30 · 245,122,000,000 USD
2024 $245.12B
2025-06-30 · 281,724,000,000 USD
2025 $281.72B
2026-06-30 · 331,839,000,000 USD
2026 $331.84B Each bar is one fiscal year of revenue, ending on the date shown.
Income statement CONSOLIDATED Line 2026 06-30 2025 06-30 2024 06-30 2023 06-30 2022 06-30 2021 06-30 2020 06-30 2019 06-30 2018 06-30 2017 06-30 Revenue $331.84B $281.72B $245.12B $211.92B $198.27B $168.09B $143.02B $125.84B $110.36B $96.57B Cost of revenue $106.37B $87.83B $74.11B $65.86B $62.65B $52.23B $46.08B $42.91B $38.35B $34.26B Gross profit $225.47B $193.89B $171.01B $146.05B $135.62B $115.86B $96.94B $82.93B $72.01B $62.31B Research and development $35.56B $32.49B $29.51B $27.2B $24.51B $20.72B $19.27B $16.88B $14.73B $13.04B Selling, general and administrative $7.96B $7.22B $7.61B $7.58B $5.9B $5.11B $5.11B $4.89B $4.75B $4.48B Operating expenses $70.23B $65.37B $61.58B $57.53B — — — — — — Operating income $155.24B $128.53B $109.43B $88.52B $83.38B $69.92B $52.96B $42.96B $35.06B $29.03B Non-operating income $10.7B $-4.9B $-1.65B $788M $333M $1.19B $77M $729M $1.42B $876M Income tax expense $32.19B $21.8B $19.65B $16.95B $10.98B $9.83B $8.76B $4.45B $19.9B $4.41B Net income $133.75B $101.83B $88.14B $72.36B $72.74B $61.27B $44.28B $39.24B $16.57B $25.49B Basic EPS 18.00 13.70 11.86 9.72 9.70 8.12 5.82 5.11 2.15 3.29 Diluted EPS 17.95 13.64 11.80 9.68 9.65 8.05 5.76 5.06 2.13 3.25 Diluted shares outstanding 7.45B 7.47B 7.47B 7.47B 7.54B 7.61B 7.68B 7.75B 7.79B 7.83B
Balance sheet CONSOLIDATED Line 2026 06-30 2025 06-30 2024 06-30 2023 06-30 2022 06-30 2021 06-30 2020 06-30 2019 06-30 2018 06-30 2017 06-30 Total assets $758.38B $619B $512.16B $411.98B $364.84B $333.78B $301.31B $286.56B $258.85B $250.31B Current assets $207.71B $191.13B $159.73B $184.26B $169.68B $184.41B $181.92B $175.55B $169.66B $162.7B Cash and equivalents $20.94B $30.24B $18.32B $34.7B $13.93B $14.22B $13.58B $11.36B $11.95B $7.66B Short-term investments $55.91B $64.32B $57.23B $76.56B $90.83B $116.11B $122.95B $122.46B $121.82B — Accounts receivable $80.88B $69.91B $56.92B $48.69B $44.26B $38.04B $32.01B $29.52B $26.48B $22.43B Inventory $1.4B $938M $1.25B $2.5B $3.74B $2.64B $1.9B $2.06B $2.66B $2.18B Property, plant and equipment $313.08B $204.97B $135.59B $95.64B $74.4B $59.72B $44.15B $36.48B $29.46B $23.73B Total liabilities $315.99B $275.52B $243.69B $205.75B $198.3B $191.79B $183.01B $184.23B $176.13B $162.6B Current liabilities $168.83B $141.22B $125.29B $104.15B $95.08B $88.66B $72.31B $69.42B $58.49B $55.75B Accounts payable $42.42B $27.72B $22B $18.1B $19B $15.16B $12.53B $9.38B $8.62B $7.39B Short-term debt $9.23B $3B $2.25B $5.25B $2.75B $8.07B $3.75B $5.52B $4B $1.05B Long-term debt $31.07B $40.15B $42.69B $41.99B $47.03B $50.07B $59.58B $66.66B $72.24B $76.07B Shareholders' equity $442.39B $343.48B $268.48B $206.22B $166.54B $141.99B $118.3B $102.33B $82.72B $87.71B Retained earnings $328.27B $237.73B $173.14B $118.85B $84.28B $57.06B $34.57B $24.15B $13.68B $17.77B
Cash flow statement CONSOLIDATED Line 2026 06-30 2025 06-30 2024 06-30 2023 06-30 2022 06-30 2021 06-30 2020 06-30 2019 06-30 2018 06-30 2017 06-30 Operating cash flow $182.94B $136.16B $118.55B $87.58B $89.04B $76.74B $60.68B $52.19B $43.88B $39.51B Investing cash flow $-139.5B $-72.6B $-96.97B $-22.68B $-30.31B $-27.58B $-12.22B $-15.77B $-6.06B $-46.78B Financing cash flow $-52.55B $-51.7B $-37.76B $-43.94B $-58.88B $-48.49B $-46.03B $-36.89B $-33.59B $8.41B Capital expenditure $115.95B $64.55B $44.48B $28.11B $23.89B $20.62B $15.44B $13.93B $11.63B $8.13B Dividends paid $26.45B $24.08B $21.77B $19.8B $18.14B $16.52B $15.14B $13.81B $12.7B $11.85B Share buybacks $22.27B $18.42B $17.25B $22.25B $32.7B $27.39B $22.97B $19.54B $10.72B $11.79B
Key ratios COMPUTED HERE Line 2026 06-30 2025 06-30 2024 06-30 2023 06-30 2022 06-30 2021 06-30 2020 06-30 2019 06-30 2018 06-30 2017 06-30 Gross margin 67.9% 68.8% 69.8% 68.9% 68.4% 68.9% 67.8% 65.9% 65.2% 64.5% Operating margin 46.8% 45.6% 44.6% 41.8% 42.1% 41.6% 37.0% 34.1% 31.8% 30.1% Net margin 40.3% 36.1% 36.0% 34.1% 36.7% 36.5% 31.0% 31.2% 15.0% 26.4% Return on equity 30.2% 29.6% 32.8% 35.1% 43.7% 43.2% 37.4% 38.3% 20.0% 29.1% Return on assets 17.6% 16.5% 17.2% 17.6% 19.9% 18.4% 14.7% 13.7% 6.4% 10.2% Asset turnover 0.44× 0.46× 0.48× 0.51× 0.54× 0.50× 0.47× 0.44× 0.43× 0.39× Current ratio 1.23× 1.35× 1.27× 1.77× 1.78× 2.08× 2.52× 2.53× 2.90× 2.92× Debt to equity 71.4% 80.2% 90.8% 99.8% 119.1% 135.1% 154.7% 180.0% 212.9% 185.4% Net debt $19.36B $12.91B $26.62B $12.53B $35.85B $43.92B $49.75B $60.82B $64.29B $69.46B Free cash flow $66.99B $71.61B $74.07B $59.48B $65.15B $56.12B $45.23B $38.26B $32.25B $31.38B Cash conversion cycle -52d -21d -17d -3d -7d -5d -3d 23d 31d 29d
Amounts are as filed. An em dash means that line was not reported, not that it is nil; rows marked “computed” and the whole key-ratios table are worked out here from those amounts.
About this record 10 fiscal years from 2017 to 2026, covering 33 statement lines, collected from SEC EDGAR. The most recent was confirmed on 2026-07-29.
Its 46.78% operating margin in the latest fiscal year is at or above 91% of the 45 listed companies collected here, closest to Samsung Biologics 45.41% and SK hynix 48.59%.
The fiscal year does not follow the calendar: the most recent one ran from 2025-07-01 to 2026-06-30. Set beside a December-year company it would be two different twelve-month periods compared as one.
This page offers no investment view or forecast about Microsoft. The amounts are as the company filed them, the ratios follow from those amounts, and no currency is converted.
Run these figures through the calculators · Reading guides · Methodology